CBDY Quote, Financials, Valuation and Earnings

Edesa Biotech, Inc. has a net margin of -95.2% compared to Target Group, Inc. (Canada)'s net margin of --. Target Group, Inc. (Canada)'s return on equity of -- beat Edesa Biotech, Inc.'s return on equity of -77.48%.

Target Group, Inc. (Canada) has a consensus price target of --, signalling downside risk potential of --. On the other hand Edesa Biotech, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 663.89%. Given that Edesa Biotech, Inc. has higher upside potential than Target Group, Inc. (Canada), analysts believe Edesa Biotech, Inc. is more attractive than Target Group, Inc. (Canada).

Target Group, Inc. (Canada) has a beta of 0.831, which suggesting that the stock is 16.923% less volatile than S&P 500. In comparison Edesa Biotech, Inc. has a beta of 0.078, suggesting its less volatile than the S&P 500 by 92.204%.

Target Group, Inc. (Canada) has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Target Group, Inc. (Canada) pays -- of its earnings as a dividend. Edesa Biotech, Inc. pays out -- of its earnings as a dividend.

Target Group, Inc. (Canada) quarterly revenues are $503.6K, which are larger than Edesa Biotech, Inc. quarterly revenues of --. Target Group, Inc. (Canada)'s net income of -$479.4K is higher than Edesa Biotech, Inc.'s net income of -$2.2M. Notably, Target Group, Inc. (Canada)'s price-to-earnings ratio is 5.67x while Edesa Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Target Group, Inc. (Canada) is 0.17x versus 31.22x for Edesa Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Lexaria Bioscience Corp. has a net margin of -95.2% compared to Target Group, Inc. (Canada)'s net margin of -2178.51%. Target Group, Inc. (Canada)'s return on equity of -- beat Lexaria Bioscience Corp.'s return on equity of -147.19%.

Target Group, Inc. (Canada) has a consensus price target of --, signalling downside risk potential of --. On the other hand Lexaria Bioscience Corp. has an analysts' consensus of $4.50 which suggests that it could grow by 747.62%. Given that Lexaria Bioscience Corp. has higher upside potential than Target Group, Inc. (Canada), analysts believe Lexaria Bioscience Corp. is more attractive than Target Group, Inc. (Canada).

Target Group, Inc. (Canada) has a beta of 0.831, which suggesting that the stock is 16.923% less volatile than S&P 500. In comparison Lexaria Bioscience Corp. has a beta of 0.628, suggesting its less volatile than the S&P 500 by 37.221%.

Target Group, Inc. (Canada) has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Target Group, Inc. (Canada) pays -- of its earnings as a dividend. Lexaria Bioscience Corp. pays out -- of its earnings as a dividend.

Target Group, Inc. (Canada) quarterly revenues are $503.6K, which are larger than Lexaria Bioscience Corp. quarterly revenues of $174K. Target Group, Inc. (Canada)'s net income of -$479.4K is higher than Lexaria Bioscience Corp.'s net income of -$2.7M. Notably, Target Group, Inc. (Canada)'s price-to-earnings ratio is 5.67x while Lexaria Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Target Group, Inc. (Canada) is 0.17x versus 13.54x for Lexaria Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Oncolytics Biotech, Inc. has a net margin of -95.2% compared to Target Group, Inc. (Canada)'s net margin of --. Target Group, Inc. (Canada)'s return on equity of -- beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.

Target Group, Inc. (Canada) has a consensus price target of --, signalling downside risk potential of --. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $5.55 which suggests that it could grow by 483.09%. Given that Oncolytics Biotech, Inc. has higher upside potential than Target Group, Inc. (Canada), analysts believe Oncolytics Biotech, Inc. is more attractive than Target Group, Inc. (Canada).

Target Group, Inc. (Canada) has a beta of 0.831, which suggesting that the stock is 16.923% less volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.880, suggesting its less volatile than the S&P 500 by 11.965%.

Target Group, Inc. (Canada) has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Target Group, Inc. (Canada) pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.

Target Group, Inc. (Canada) quarterly revenues are $503.6K, which are larger than Oncolytics Biotech, Inc. quarterly revenues of --. Target Group, Inc. (Canada)'s net income of -$479.4K is higher than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, Target Group, Inc. (Canada)'s price-to-earnings ratio is 5.67x while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Target Group, Inc. (Canada) is 0.17x versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xenon Pharmaceuticals, Inc. has a net margin of -95.2% compared to Target Group, Inc. (Canada)'s net margin of -867.29%. Target Group, Inc. (Canada)'s return on equity of -- beat Xenon Pharmaceuticals, Inc.'s return on equity of -44.39%.

Target Group, Inc. (Canada) has a consensus price target of --, signalling downside risk potential of --. On the other hand Xenon Pharmaceuticals, Inc. has an analysts' consensus of $55.40 which suggests that it could grow by 23.56%. Given that Xenon Pharmaceuticals, Inc. has higher upside potential than Target Group, Inc. (Canada), analysts believe Xenon Pharmaceuticals, Inc. is more attractive than Target Group, Inc. (Canada).

Target Group, Inc. (Canada) has a beta of 0.831, which suggesting that the stock is 16.923% less volatile than S&P 500. In comparison Xenon Pharmaceuticals, Inc. has a beta of 1.027, suggesting its more volatile than the S&P 500 by 2.689%.

Target Group, Inc. (Canada) has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Target Group, Inc. (Canada) pays -- of its earnings as a dividend. Xenon Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Target Group, Inc. (Canada) quarterly revenues are $503.6K, which are larger than Xenon Pharmaceuticals, Inc. quarterly revenues of --. Target Group, Inc. (Canada)'s net income of -$479.4K is higher than Xenon Pharmaceuticals, Inc.'s net income of -$90.9M. Notably, Target Group, Inc. (Canada)'s price-to-earnings ratio is 5.67x while Xenon Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Target Group, Inc. (Canada) is 0.17x versus 471.23x for Xenon Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.